Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | PYGL | P06737 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CTSD | P07339 | 1/20 | 0.30 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | CTSB | P07858 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11987474 | 0.89 | AAK1 (0.38) | AAK1 | |
| SCHEMBL1054147 | 0.88 | CTSS (0.35) | AAK1PYGLMMP13KMT2ACTSS | |
| SCHEMBL1706279 | 0.88 | CTSS (0.35) | AAK1PYGLMMP13KMT2ACTSS | |
| SCHEMBL1054148 | 0.88 | CTSS (0.35) | AAK1PYGLMMP13KMT2ACTSS | |
| SCHEMBL1054144 | 0.88 | CTSS (0.35) | AAK1PYGLMMP13KMT2ACTSS | |
| SCHEMBL10182733 | 0.82 | AAK1 (0.34) | AAK1KMT2A | |
| SCHEMBL13576857 | 0.82 | PYGL (0.35) | PYGLCYP2C9 | |
| SCHEMBL1691482 | 0.78 | AAK1 (0.53) | AAK1PYGLCYP2C9KMT2ACTSL | |
| SCHEMBL16097567 | 0.78 | AAK1 (0.53) | AAK1PYGLCYP2C9KMT2ACTSL | |
| SCHEMBL3370249 | 0.78 | AAK1 (0.53) | AAK1PYGLCYP2C9KMT2ACTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040706-B2 | Pyrrolidine inhibitors of IAP | GENENTECH, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040706-B2 | Pyrrolidine inhibitors of IAP | GENENTECH, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-8907092-B2 | Inhibitors of IAP | GENENTECH, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140080805-A1 | PYRROLIDINE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140080805-A1 | PYRROLIDINE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| EP-1836201-B2 | PYRROLIDINE INHIBITORS OF IAP | GENENTECH INC (US) | 2013-09-04 | — | — | EP | disclosed |
| EP-2240506-B1 | INHIBITORS OF IAP | GENENTECH INC (US) | 2012-12-26 | — | — | EP | disclosed |
| US-20120270886-A1 | INHIBITORS OF IAP | KOEHLER MICHAEL F T (US) | 2012-10-25 | — | — | US | disclosed |
| US-8247557-B2 | IAP inhibitors | GENENTECH, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247557-B2 | IAP inhibitors | GENENTECH, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| WO-2010021934-A2 | AZAINDOLE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20090318409-A1 | PYRROLIDINE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090318409-A1 | PYRROLIDINE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090221630-A1 | IAP INHIBITORS | GENENTECH, INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221630-A1 | IAP INHIBITORS | GENENTECH, INC. | 2009-09-03 | — | — | US | disclosed |
| WO-2009089502-A1 | INHIBITORS OF IAP | GENENTECH, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| US-20090176822-A1 | PYRROLIDINE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176822-A1 | PYRROLIDINE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| WO-2008134679-A1 | INHIBITORS OF IAP | GENENTECH, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008079735-A1 | IMIDAZOPYRIDINE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221630-A1 | IAP INHIBITORS | XIAP, BIRC5, BIRC3 | AAK1 1553/4885PYGL 2661/4885CYP2C9 4869/4885 |
| US-20090176822-A1 | PYRROLIDINE INHIBITORS OF IAP | BIRC5, XIAP, BIRC2 | AAK1 1999/4885PYGL 2738/4885CYP2C9 4869/4885 |
| US-20120270886-A1 | INHIBITORS OF IAP | XIAP, BIRC5, BIRC3 | AAK1 1731/4885PYGL 2807/4885CYP2C9 4876/4885 |
| US-20140080805-A1 | PYRROLIDINE INHIBITORS OF IAP | BIRC5, XIAP, BIRC2 | AAK1 1999/4885PYGL 2738/4885CYP2C9 4869/4885 |
| US-20090318409-A1 | PYRROLIDINE INHIBITORS OF IAP | BIRC5, XIAP, BIRC2 | AAK1 1999/4885PYGL 2738/4885CYP2C9 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.